Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(11 sites)
France
Novartis Investigative Site, Bordeaux Novartis Investigative Site, Brest Novartis Investigative Site, Le Kremlin-Bicêtre Novartis Investigative Site, Lille Germany
Novartis Investigative Site, Freiburg im Breisgau, Baden-Wurttemberg Novartis Investigative Site, Cologne, North Rhine-Westphalia Novartis Investigative Site, Berlin Novartis Investigative Site, Ulm Singapore
Novartis Investigative Site, Singapore Spain
Novartis Investigative Site, Barcelona Novartis Investigative Site, Madrid